We caught up with Dr. Andrew Blauvelt (Oregon Medical Research Center, Portland, OR, USA) to discuss the rationale for and findings from the proof-of-concept study of eblasakimab in moderate-to-severe atopic dermatitis.
The abstract ‘Eblasakimab, a human anti-IL-13 receptor monoclonal antibody, in adult patients with moderate-to-severe atopic dermatitis: a randomized, double-blinded, placebo-controlled, proof-of-concept study’ was presented at AAD-VMX 2022, 25-29 March.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the AAD. Â
Questions
- What has been the impact of anti-IL receptor antibodies in the treatment of atopic dermatitis? (0:14)
- What unmet needs remain in the treatment of moderate-to-severe atopic dermatitis? (0:59)
- What is eblasakimab and what is the rationale for its use in atopic dermatitis? (2:19)
- Could you tell us a little about the proof-of-concept study and its findings? (3:40)
- What will be the next steps in the clinical development of eblasakimab? (5:38)
Disclosures: Andrew Blauvelt has served as a speaker/received honoraria from AbbVie and UCB, served as a scientific adviser/received honoraria from AbbVie, Abcentra, Aligos, Almirall, Amgen, Anaptysbio, Arcutis, Arena, Aslan, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, EcoR1, Eli Lilly and Company, Evommune, Forte, Galderma, HighlightII Pharma, Incyte, Janssen, Landos, Leo, Merck, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, UCB Pharma, Vibliome, and Xencor, and has acted as a clinical study investigator/institution has received clinical study funds from AbbVie, Amgen, Arcutis, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly and Company, Galderma, Incyte, Janssen, Leo, Merck, Novartis, Pfizer, Regeneron, Sun Pharma, and UCB Pharma.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the AAD-VMX annual meeting 2022.
